Search
for
Sort by
Research 61–90 of 1000+
- Early embryonic exposure of freshwater gastropods to pharmaceutical 5-alpha-reductase inhibitors results in a surprising open-coiled “banana-shaped” shell
- Exploring the Inhibitory Potential of Phytosterols β-Sitosterol, Stigmasterol, and Campesterol on 5-Alpha Reductase Activity in the Human Prostate: An In Vitro and In Silico Approach
- May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
- Chemical Mechanism of the Covalent Modification of 5.alpha.-Reductases by Finasteride as Probed by Secondary Tritium Isotope Effects
- Predominant expression of 5 alpha-reductase type 1 in pubic skin from normal subjects and hirsute patients.
- Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment
- Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors
- Changes in serum free testosterone, sleep patterns, and 5‐alpha‐reductase type I activity influence changes in sebum excretion in female subjects
- Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?
- An Old Problem with a New Cause-5 Alpha Reductase Inhibitors and Persistent Sexual Dysfunction
- Phytochemicals With Anti 5-alpha-reductase Activity: A Prospective For Prostate Cancer Treatment
- 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
- Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor.
- Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
- Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
- Sexual Dysfunctions Related to Drugs Used in the Management of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: A Narrative Review on α-Blockers and 5-Alpha Reductase Inhibitors
- Long-term efficacy and safety of the dual 5-alpha reductase blocker dutasteride on male androgenetic alopecia patients
- Long-Term Experience With 5-alpha-Reductase Inhibitors.
- 5-Alpha-Reductase Inhibitors Reduce Remission Time of COVID-19: Results From a Randomized Double Blind Placebo Controlled Interventional Trial in 130 SARS-CoV-2 Positive Men
- Effects of 5‐alpha reductase inhibitors on lung function: A reason for discontinuation duringCOVID‐19 pandemic?
- Homology Modeling of 5-alpha-Reductase 2 Using Available Experimental Data
- Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia.
- The connection of 5-alpha reductase inhibitors to the development of depression
- Possible role of 5-alpha reductase inhibitors in non-invasive bladder urothelial neoplasm: multicentre study
- Risk of Depression after 5 Alpha Reductase Inhibitor Medication: Meta-Analysis
- 5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis
- Intraethnic variation in steroid-5-alpha-reductase polymorphisms in prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment
- Theoretical Evaluation of Twenty-Cannabinoid Derivatives on Either Androgen Receptor or 5α-Reductase Enzyme
- Identification of Beta-Sitosterol and Stigmasterol as Possible Inhibitors of 5 Alpha-Reductase 1: An In-Silico Study
- Three-Dimensional Proteome-Wide Scale Screening for the 5-Alpha Reductase Inhibitor Finasteride: Identification of a Novel Off-Target